Evidence map›Paper›PMID 41563717›Full record

Observational studyClinical and translational gastroenterology2026

Combining Cytokine-Related Biomarkers to Better Define Tumor Necrosis Factor-α Antagonist Response in Inflammatory Bowel Disease: An Observational Cohort Study.

Eryn Rooney, Gio R Dela Cruz, Terry Ponich, James C Gregor, Nilesh Chande, Melanie D Beaton, Michael Sey, Reena Khanna, Richard B Kim, Aze Wilson

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical and translational gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eryn RooneyDepartment of Physiology and Pharmacology, Western University, London, Ontario, Canada.
Gio R Dela CruzDepartment of Medicine, Division of Clinical Pharmacology, Western University, London, Ontario, Canada.
Terry PonichDepartment of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada .
James C GregorDepartment of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada .
Nilesh ChandeDepartment of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada .
Melanie D BeatonDepartment of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada .
Michael SeyDepartment of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada .
Reena KhannaDepartment of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada .
Richard B KimDepartment of Physiology and Pharmacology, Western University, London, Ontario, Canada.
Aze WilsonDepartment of Physiology and Pharmacology, Western University, London, Ontario, Canada.ORCID 0000-0001-6568-1714

Funding

Wolfe Medical Research Chair in Pharmacogenomics, Canadian Institutes of Health Team Grant: Personalized Health FRN 178435
6 · The paper itself

Abstract

introductionInterleukin-13 receptor alpha 2 (IL13RA2), triggering receptor expressed on myeloid cells-1 (TREM-1), and oncostatin M (OSM) may be associated with response to tumor necrosis factor-α antagonists (TNFAs) in inflammatory bowel disease. We aimed to assess the direction of association between TNFA-induced clinical remission and IL13RA2 and TREM-1, respectively, and assess the value of combining biomarkers for identifying nonresponders.

methodsPlasma samples from a retrospective inflammatory bowel disease cohort were collected before TNFA start. Clinical remission at 1-year, surgery, hospitalization, adverse drug events, and TNFA discontinuation were assessed. IL13RA2 and TREM-1 concentrations were compared between those with and without 1-year clinical remission. OSM data were obtained from our previous cohort. Where significant, TREM-1 and IL23RA2 thresholds associated with clinical remission at 1-year were assessed using a receiver operating characteristic analysis. Significant biomarkers were combined using a linear discriminant analysis. The performance characteristics were assessed for individual biomarkers and biomarker combinations.

resultsIn Crohn's disease (CD) (n = 95) and ulcerative colitis (UC) (n = 53), higher IL13RA2 concentrations, but not TREM-1, were found among those not achieving TNFA-associated clinical remission at 1-year (IL13RA2, CD, P < 0.0001; UC, P = 0.0003). IL13RA2 thresholds, 4.554 ng/mL (CD) and 6.117 ng/mL (UC) separated those with and without clinical remission at 1-year (CD, area under the receiver-operating characteristic curve = 0.80, 95% CI = 0.71-0.90, P < 0.0001; UC, area under the receiver-operating characteristic curve = 0.79, 95% CI = 0.66-0.91, P = 0.0005). In CD, combining IL13RA2 and OSM concentrations enhanced prediction accuracy compared with either biomarker alone and increased the identification of other important clinical outcomes. DISCUSSION: IL13RA2, but not TREM-1, was associated with TNFA response. In CD, its prediction accuracy improves when combined with OSM.

Indexed as

Colitis, UlcerativeCrohn DiseaseInterleukin-13 Receptor alpha2 SubunitTriggering Receptor Expressed on Myeloid Cells-1Tumor Necrosis Factor-alphaAdultBiomarkersFemaleHumansMaleMiddle AgedOncostatin MRemission InductionRetrospective StudiesROC CurveTreatment OutcomeBiomarkersInterleukin-13 Receptor alpha2 SubunitOncostatin MTREM1 protein, humanTriggering Receptor Expressed on Myeloid Cells-1Tumor Necrosis Factor-alphaIL13RA2inflammatory bowel diseaseoncostatin-MTREM-1tumor necrosis factor-α antagonist

Identifiers

PMID41563717
PMCPMC12922915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.